Perinatal Institute, Section of Neonatology, Perinatal and Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA.
Annu Rev Med. 2010;61:105-19. doi: 10.1146/annurev.med.60.041807.123500.
The alveolar region of the lung creates an extensive epithelial surface that mediates the transfer of oxygen and carbon dioxide required for respiration after birth. Maintenance of pulmonary function depends on the function of type II epithelial cells that synthesize and secrete pulmonary surfactant lipids and proteins, reducing the collapsing forces created at the air-liquid interface in the alveoli. Genetic and acquired disorders associated with the surfactant system cause both acute and chronic lung disease. Mutations in the ABCA3, SFTPA, SFTPB, SFTPC, SCL34A2, and TERT genes disrupt type II cell function and/or surfactant homeostasis, causing neonatal respiratory failure and chronic interstitial lung disease. Defects in GM-CSF receptor function disrupt surfactant clearance, causing pulmonary alveolar proteinosis. Abnormalities in the surfactant system and disruption of type II cell homeostasis underlie the pathogenesis of pulmonary disorders previously considered idiopathic, providing the basis for improved diagnosis and therapies of these rare lung diseases.
肺的肺泡区域形成广泛的上皮表面,介导出生后呼吸所需的氧气和二氧化碳的转移。肺功能的维持依赖于合成和分泌肺表面活性物质脂质和蛋白质的 II 型上皮细胞的功能,从而降低肺泡中液-气界面产生的塌陷力。与表面活性物质系统相关的遗传和获得性疾病会导致急性和慢性肺部疾病。ABCA3、SFTPA、SFTPB、SFTPC、SCL34A2 和 TERT 基因的突变会破坏 II 型细胞功能和/或表面活性物质的动态平衡,导致新生儿呼吸衰竭和慢性间质性肺病。GM-CSF 受体功能缺陷会破坏表面活性物质的清除,导致肺泡蛋白沉积症。表面活性物质系统的异常和 II 型细胞动态平衡的破坏是先前被认为是特发性的肺部疾病的发病机制基础,为这些罕见肺部疾病的改善诊断和治疗提供了依据。